<!DOCTYPE html>
<html lang="en">
  <head>
      <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <link rel="stylesheet" href="/css/custom.css">
  <link href="https://fonts.googleapis.com/css2?family=PT+Serif&family=Source+Sans+Pro&display=swap" rel="stylesheet">

    <title>多巴胺与近视发展 | Nutr1t07's Blog</title>
  </head>

  <body>
    <div class="container">
            <div class="sidebar">
            <nav>
                <h3 id="logo">Nutr1t07</h3>
                <ul>
                    <li><a href="/">Index</a></li>
                    <li><a href="/page/friends/">Friends</a></li>
                </ul>
            </nav>
            &nbsp;
      </div>

      <div class="content">
        <h3>多巴胺与近视发展</h3>
        <p>多巴胺是视网膜中重要的神经递质，介导多种功能，包括视觉传递和屈光发育。<sup id="fnref:1"><a href="#fn:1">1</a>
</sup>
来自不同物种的几个实验数据表明，多巴胺起抑制屈光发育的作用。<sup id="fnref:2"><a href="#fn:2">2</a>
</sup>
该现象体现于灵长类动物、鸡和豚鼠形觉剥夺后带来的视网膜或玻璃体的多巴胺和/或3,4-二羟基苯乙酸(视网膜中多巴胺的主要代谢产物)水平降低。<sup id="fnref:3"><a href="#fn:3">3</a>
</sup></p>
<p>如果近视眼发育期间多巴胺水平降低和/或信号传导减少，则可预测增加多巴胺水平和多巴胺受体活性能预防近视。实验说明，多巴胺水平提升和使用多巴胺受体激动剂增加多巴胺信号传导，可防止几种动物的形觉剥夺性近视。<sup id="fnref:4"><a href="#fn:4">4</a>
</sup>
这些研究表明，在异常视觉条件(如形觉剥夺)下生长的常规屈光眼生长缺少多巴胺受体激活，且增加眼内多巴胺水平可以防止近视生长。</p>
<p>另有研究显示室外活动与近视发展呈反比关系<sup id="fnref:5"><a href="#fn:5">5</a>
</sup>
，其中一个备受关注的领域是强光对近视发展的保护作用，并可能通过多巴胺信号传导。在户外度过更多时间的儿童会延迟近视发作。<sup id="fnref:6"><a href="#fn:6">6</a>
</sup>
这是由于强光，而不是活动或其他因素。<sup id="fnref:7"><a href="#fn:7">7</a>
</sup>
这些保护作用归因于视网膜多巴胺水平升高和多巴胺受体激活，因为多巴胺D2样受体拮抗剂螺哌隆酮(Spiperone)能够阻断强光的这种保护作用。<sup id="fnref:8"><a href="#fn:8">8</a>
</sup>
多巴胺的释放会根据光照强度和图像对比度进行调控，两者都由感光细胞检测且与近视发展有关。因此，暴露于强光可以是通过增加视网膜中的多巴胺水平来控制近视发展的环境干预式方法。视网膜多巴胺可通过触发视网膜或脉络膜中的一氧化氮释放而诱发脉络膜增厚和眼球生长抑制。<sup id="fnref:9"><a href="#fn:9">9</a>
</sup></p>
<p>此外，动物研究显示亮光减少近视是在标准实验室条件下完成的，其亮度和色度没有改变，不能模拟真实世界的自然环境，因为自然环境中的亮度会根据一天中的时间不断变化。这可能造成室外光线照射对雏鸡形觉剥夺性近视发育具有不同影响。<sup id="fnref:10"><a href="#fn:10">10</a>
</sup>
 这些观察结果表明，治疗近视的药理学方法可能比环境干预更有效。</p>
<p>从开发基于多巴胺的治疗策略的角度来看，多巴胺药物治疗儿童具有一定的潜在毒理学后果。多巴胺是脑和视网膜中的主要神经递质，也是心血管，内分泌和免疫功能的重要生理调节剂。在发育中的大脑中，多巴胺系统的过度激活已被证明会产生类似精神分裂症的行为改变。<sup id="fnref:11"><a href="#fn:11">11</a>
</sup>
与这些临床前研究一致，在少数近视儿童的L-DOPA(3,4-二羟苯丙氨酸)临床试验中发现了一些轻微的副作用，包括恶心，头痛，疲劳，情绪变化，呕吐，头晕，口干，食欲下降和梦魇；联合使用卡维多巴(一种外周多巴脱羧酶抑制剂)与L-DOPA可减少副作用。<sup id="fnref:12"><a href="#fn:12">12</a>
</sup>
此外，在开发用兴奋剂治疗注意力缺陷障碍(ADD)/注意力缺陷多动障碍(ADHD)的儿童，通过增加大脑中的细胞外多巴胺水平(包括利他林，Adderall和Dexedrine)，常见的副作用包括感觉不安和紧张，睡眠困难，食欲不振，头痛，胃部不适，烦躁，情绪波动，抑郁，头晕，心跳加速和抽搐。<sup id="fnref:13"><a href="#fn:13">13</a>
</sup>
美国心脏协会建议所有人，包括儿童，在开始兴奋剂之前进行心脏评估。<sup id="fnref:14"><a href="#fn:14">14</a>
</sup>
此外，ADD/ADHD药物对年轻、正在发育的大脑的长期影响尚不清楚。</p>
<p>然而，多巴胺受体激动剂可提供具有较少副作用的治疗选择。 多巴胺受体激动剂目前已获FDA批准用于治疗各种疾病，包括帕金森病，不安腿综合征和糖尿病。然而，在发育的关键时期使用多巴胺受体激动剂可能是有害的。 多巴胺受体对葡萄糖代谢具有深远影响。<sup id="fnref:14"><a href="#fn:14">14</a>
</sup>
因此，在多巴胺受体激动剂可被视为儿童的抗近视药物之前，必须对多巴胺对视觉和全身功能的可能副作用进行广泛研究。</p>
<p>* 翻译，裁剪自: <em>Zhou X, Pardue MT, Iuvone PM, Qu J. Dopamine signaling and myopia development: What are the key challenges. Prog Retin Eye Res. 2017; 61: 60–71.</em></p>
<div id="footnotes"><hr/><ol>
<li id="fn:1"><ul>
<li>Witkovsky P. Dopamine and retinal function. Doc Ophthalmol. 2004;108:17–40.</li>
</ul>
<a href="#fnref:1" >↩</a></li>
<li id="fn:2"><ul>
<li>Feldkaemper M, Schaeffel F. An updated view on the role of dopamine in myopia. Exp Eye Res. 2013;114:106–119.</li>
</ul>
<a href="#fnref:2" >↩</a></li>
<li id="fn:3"><ul>
<li>Dong F, Zhi Z, Pan M, Xie R, Qin X, Lu R, Mao X, Chen JF, Willcox MD, Qu J, Zhou X. Inhibition of experimental myopia by a dopamine agonist: different effectiveness between form deprivation and hyperopic defocus in guinea pigs. Mol Vis. 2011b;17:2824–2834.</li>
</ul>
<ul>
<li>Iuvone PM, Tigges M, Fernandes A, Tigges J. Dopamine synthesis and metabolism in rhesus monkey retina: development, aging, and the effects of monocular visual deprivation. Vis Neurosci. 1989;2:465–471.</li>
</ul>
<ul>
<li>McBrien NA, Gentle A. The role of visual information in the control of scleral matrix biology in myopia. Curr Eye Res. 2001;23:313–319.</li>
</ul>
<ul>
<li>Papastergiou GI, Schmid GF, Laties AM, Pendrak K, Lin T, Stone RA. Induction of axial eye elongation and myopic refractive shift in one-year-old chickens. Vision Res. 1998;38:1883–1888.</li>
</ul>
<ul>
<li>Stone RA, Lin T, Laties AM, Iuvone PM. Retinal dopamine and form-deprivation myopia. Proc Natl Acad Sci U S A. 1989;86:704–706.</li>
</ul>
<a href="#fnref:3" >↩</a></li>
<li id="fn:4"><ul>
<li>Mao J, Liu S, Qin W, Li F, Wu X, Tan Q. Levodopa inhibits the development of form-deprivation myopia in guinea pigs. Optom Vis Sci. 2010;87:53–60.</li>
</ul>
<ul>
<li>Gao Q, Liu Q, Ma P, Zhong X, Wu J, Ge J. Effects of direct intravitreal dopamine injections on the development of lid-suture induced myopia in rabbits. Graefes Arch Clin Exp Ophthalmol. 2006;244:1329–1335.</li>
</ul>
<ul>
<li>Stone RA, Lin T, Laties AM, Iuvone PM. Retinal dopamine and form-deprivation myopia. Proc Natl Acad Sci U S A. 1989;86:704–706.</li>
</ul>
<ul>
<li>Landis E, Park H, Chakraborty R, Sidhu C, Iuvone PM, Pardue MT. Ascorbic acid, and not L-DOPA, protects against form-deprivation myopia in retinal degeneration mouse models. Invest Ophthalmol Vis Sci. 2016;57 E-Absract No pagination specified.</li>
</ul>
<ul>
<li>Rohrer B, Spira AW, Stell WK. Apomorphine blocks form-deprivation myopia in chickens by a dopamine D2-receptor mechanism acting in retina or pigmented epithelium. Vis Neurosci. 1993;10:447–453.</li>
</ul>
<ul>
<li>Schmid KL, Wildsoet CF. Inhibitory effects of apomorphine and atropine and their combination on myopia in chicks. Optom Vis Sci. 2004;81:137–147.</li>
</ul>
<ul>
<li>Yan T, Xiong W, Huang F, Zheng F, Ying H, Chen JF, Qu J, Zhou X. Daily Injection But Not Continuous Infusion of Apomorphine Inhibits Form-Deprivation Myopia in Mice. Invest Ophthalmol Vis Sci. 2015b;56:2475–2485.</li>
</ul>
<ul>
<li>Ashby R, McCarthy CS, Maleszka R, Megaw P, Morgan IG. A muscarinic cholinergic antagonist and a dopamine agonist rapidly increase ZENK mRNA expression in the form-deprived chicken retina. Exp Eye Res. 2007;85:15–22.</li>
</ul>
<ul>
<li>Dong F, Zhi Z, Pan M, Xie R, Qin X, Lu R, Mao X, Chen JF, Willcox MD, Qu J, Zhou X. Inhibition of experimental myopia by a dopamine agonist: different effectiveness between form deprivation and hyperopic defocus in guinea pigs. Mol Vis. 2011b;17:2824–2834.</li>
</ul>
<ul>
<li>Iuvone PM, Tigges M, Stone RA, Lambert S, Laties AM. Effects of apomorphine, a dopamine receptor agonist, on ocular refraction and axial elongation in a primate model of myopia. Invest Ophthalmol Vis Sci. 1991;32:1674–1677.</li>
</ul>
<ul>
<li>McCarthy CS, Megaw P, Devadas M, Morgan IG. Dopaminergic agents affect the ability of brief periods of normal vision to prevent form-deprivation myopia. Exp Eye Res. 2007;84:100–107.</li>
</ul>
<a href="#fnref:4" >↩</a></li>
<li id="fn:5"><ul>
<li>Cohen Y, Peleg E, Belkin M, Polat U, Solomon AS. Ambient illuminance, retinal dopamine release and refractive development in chicks. Exp Eye Res. 2012;103:33–40.</li>
</ul>
<ul>
<li>Proll MA, Kamp CW, Morgan WW. Use of liquid chromatography with electrochemistry to measure effects of varying intensities of white light on DOPA accumulation in rat retinas. Life sciences. 1982;30:11–19.</li>
</ul>
<a href="#fnref:5" >↩</a></li>
<li id="fn:6"><ul>
<li>Guggenheim JA, Northstone K, McMahon G, Ness AR, Deere K, Mattocks C, Pourcain BS, Williams C. Time outdoors and physical activity as predictors of incident myopia in childhood: a prospective cohort study. Invest Ophthalmol Vis Sci. 2012;53:2856–2865.</li>
</ul>
<ul>
<li>Rose KA, Morgan IG, Ip J, Kifley A, Huynh S, Smith W, Mitchell P. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115:1279–1285.</li>
</ul>
<ul>
<li>Sherwin JC, Reacher MH, Keogh RH, Khawaja AP, Mackey DA, Foster PJ. The association between time spent outdoors and myopia in children and adolescents: a systematic review and meta-analysis. Ophthalmology. 2012;119:2141–2151.</li>
</ul>
<a href="#fnref:6" >↩</a></li>
<li id="fn:7"><ul>
<li>Read SA, Collins MJ, Vincent SJ. Light exposure and physical activity in myopic and emmetropic children. Optom Vis Sci. 2014;91:330–341.</li>
</ul>
<ul>
<li>Rose KA, Morgan IG, Ip J, Kifley A, Huynh S, Smith W, Mitchell P. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115:1279–1285.</li>
</ul>
<a href="#fnref:7" >↩</a></li>
<li id="fn:8"><ul>
<li>Ashby RS, Schaeffel F. The effect of bright light on lens compensation in chicks. Invest Ophthalmol Vis Sci. 2010;51:5247–5253.</li>
</ul>
<a href="#fnref:8" >↩</a></li>
<li id="fn:9"><ul>
<li>Nickla DL, Damyanova P, Lytle G. Inhibiting the neuronal isoform of nitric oxide synthase has similar effects on the compensatory choroidal and axial responses to myopic defocus in chicks as does the non-specific inhibitor L-NAME. Exp Eye Res. 2009;88:1092–1099.</li>
</ul>
<ul>
<li>Sekaran S, Cunningham J, Neal MJ, Hartell NA, Djamgoz MB. Nitric oxide release is induced by dopamine during illumination of the carp retina: serial neurochemical control of light adaptation. Eur J Neurosci. 2005;21:2199–2208.</li>
</ul>
<ul>
<li>Nickla DL, Wildsoet CF. The effect of the nonspecific nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on the choroidal compensatory response to myopic defocus in chickens. Optom Vis Sci. 2004;81:111–118.</li>
</ul>
<a href="#fnref:9" >↩</a></li>
<li id="fn:10"><ul>
<li>Stone RA, Cohen Y, McGlinn AM, Davison S, Casavant S, Shaffer J, Khurana TS, Pardue MT, Iuvone PM. Development of Experimental Myopia in Chicks in a Natural Environment. Invest Ophthalmol Vis Sci. 2016;57:4779–4789.</li>
</ul>
<ul>
<li>Ashby R, Ohlendorf A, Schaeffel F. The effect of ambient illuminance on the development of deprivation myopia in chicks. Invest Ophthalmol Vis Sci. 2009;50:5348–5354.</li>
</ul>
<a href="#fnref:10" >↩</a></li>
<li id="fn:11"><ul>
<li>Angrist B. Amphetamine and its analogues. Academic; San Diego: 1994. Amphetamine psychosis: clinical variations of the syndrome; pp. 387–414.</li>
</ul>
<a href="#fnref:11" >↩</a></li>
<li id="fn:12"><ul>
<li>Angrist B. Amphetamine and its analogues. Academic; San Diego: 1994. Amphetamine psychosis: clinical variations of the syndrome; pp. 387–414.</li>
</ul>
<ul>
<li>Repka MX, Kraker RT, Beck RW, Atkinson CS, Bacal DA, Bremer DL, Davis PL, Gearinger MD, Glaser SR, Hoover DL, Laby DM, Morrison DG, Rogers DL, Sala NA, Suh DW, Wheeler MB Pediatric Eye Disease Investigator G. Pilot study of levodopa dose as treatment for residual amblyopia in children aged 8 years to younger than 18 years. Archives of ophthalmology. 2010;128:1215–1217.</li>
</ul>
<a href="#fnref:12" >↩</a></li>
<li id="fn:13"><ul>
<li>Jeffers A, Benotsch EG, Koester S. Misuse of prescription stimulants for weight loss, psychosocial variables, and eating disordered behaviors. Appetite. 2013;65:8–13.</li>
</ul>
<ul>
<li>Salardini E, Zeinoddini A, Kohi A, Mohammadi MR, Mohammadinejad P, Khiabany M, Shahriari M, Akhondzadeh S. Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial. J Child Adol Psychop. 2016;26:513–519.</li>
</ul>
<a href="#fnref:13" >↩</a></li>
<li id="fn:14"><ul>
<li>Thomas PE, Carlo WF, Decker JA, Cannon BC, Kertesz NJ, Friedman RA, Kim JJ. Impact of the American Heart Association Scientific Statement on Screening Electrocardiograms and Stimulant Medications. Arch Pediat Adol Med. 2011;165:166–170.</li>
</ul>
<a href="#fnref:14" >↩</a></li>
</ol>
</div>
      </div>
    </div>
  </body>
</html>
